A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations

PURPOSE: To determine the safety and efficacy of PARP plus PD-L1 inhibition (olaparib + durvalumab, O + D) in patients with advanced solid, predominantly rare cancers harbouring homologous recombination repair (HRR) defects. PATIENTS AND METHODS: In total, 48 patients were treated with O + D, 16 wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Thavaneswaran, Subotheni, Kansara, Maya, Lin, Frank, Espinoza, David, Grady, John P., Lee, Chee Khoon, Ballinger, Mandy L., Sebastian, Lucille, Corpuz, Theresa, Qiu, Min Ru, Mundra, Piyushkumar, Bailey, Charles G., Schmitz, Ulf, Simes, John, Joshua, Anthony M., Thomas, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403555/
https://www.ncbi.nlm.nih.gov/pubmed/37365284
http://dx.doi.org/10.1038/s41416-023-02311-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403555/
https://www.ncbi.nlm.nih.gov/pubmed/37365284
http://dx.doi.org/10.1038/s41416-023-02311-0

Ejemplares similares